These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 28639178)

  • 1. Effective Skin Cancer Treatment by Topical Co-delivery of Curcumin and STAT3 siRNA Using Cationic Liposomes.
    Jose A; Labala S; Ninave KM; Gade SK; Venuganti VVK
    AAPS PharmSciTech; 2018 Jan; 19(1):166-175. PubMed ID: 28639178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Co-delivery of curcumin and STAT3 siRNA using deformable cationic liposomes to treat skin cancer.
    Jose A; Labala S; Venuganti VV
    J Drug Target; 2017 Apr; 25(4):330-341. PubMed ID: 27819148
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effective melanoma cancer suppression by iontophoretic co-delivery of STAT3 siRNA and imatinib using gold nanoparticles.
    Labala S; Jose A; Chawla SR; Khan MS; Bhatnagar S; Kulkarni OP; Venuganti VVK
    Int J Pharm; 2017 Jun; 525(2):407-417. PubMed ID: 28373100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transcutaneous iontophoretic delivery of STAT3 siRNA using layer-by-layer chitosan coated gold nanoparticles to treat melanoma.
    Labala S; Jose A; Venuganti VV
    Colloids Surf B Biointerfaces; 2016 Oct; 146():188-97. PubMed ID: 27318964
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-delivery of Aurora-A inhibitor XY-4 and Bcl-xl siRNA enhances antitumor efficacy for melanoma therapy.
    Duan X; Mu M; Yan J; Bai L; Zhong L; Zhu Y; Pan H; Zhang M; Shi J
    Int J Nanomedicine; 2018; 13():1443-1456. PubMed ID: 29563798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradermal delivery of STAT3 siRNA to treat melanoma via dissolving microneedles.
    Pan J; Ruan W; Qin M; Long Y; Wan T; Yu K; Zhai Y; Wu C; Xu Y
    Sci Rep; 2018 Jan; 8(1):1117. PubMed ID: 29348670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Co-delivery of Bmi1 small interfering RNA with ursolic acid by folate receptor-targeted cationic liposomes enhances anti-tumor activity of ursolic acid
    Li W; Yan R; Liu Y; He C; Zhang X; Lu Y; Khan MW; Xu C; Yang T; Xiang G
    Drug Deliv; 2019 Dec; 26(1):794-802. PubMed ID: 31366257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of curcumin-loaded cationic liposome on anticancer activity for cervical cancer therapy.
    Saengkrit N; Saesoo S; Srinuanchai W; Phunpee S; Ruktanonchai UR
    Colloids Surf B Biointerfaces; 2014 Feb; 114():349-56. PubMed ID: 24246195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH-Sensitive carboxymethyl chitosan-modified cationic liposomes for sorafenib and siRNA co-delivery.
    Yao Y; Su Z; Liang Y; Zhang N
    Int J Nanomedicine; 2015; 10():6185-97. PubMed ID: 26491291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cationic liposome decorated with cyclic RGD peptide for targeted delivery of anti-STAT3 siRNA to melanoma cancer cells.
    Khabazian E; Vakhshiteh F; Norouzi P; Fatahi Y; Dinarvand R; Atyabi F
    J Drug Target; 2022 Jun; 30(5):522-533. PubMed ID: 34482780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of a carrier system containing hyaluronic acid and protamine for siRNA delivery in the treatment of melanoma.
    Yang J; Zhao R; Feng Q; Zhuo X; Wang R
    Invest New Drugs; 2021 Feb; 39(1):66-76. PubMed ID: 32794135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trilysinoyl oleylamide-based cationic liposomes for systemic co-delivery of siRNA and an anticancer drug.
    Shim G; Han SE; Yu YH; Lee S; Lee HY; Kim K; Kwon IC; Park TG; Kim YB; Choi YS; Kim CW; Oh YK
    J Control Release; 2011 Oct; 155(1):60-6. PubMed ID: 20971142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. siRNA delivery to lung-metastasized tumor by systemic injection with cationic liposomes.
    Hattori Y; Nakamura A; Arai S; Kawano K; Maitani Y; Yonemochi E
    J Liposome Res; 2015; 25(4):279-86. PubMed ID: 25543847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumor activities of novel glycyrrhetinic acid-modified curcumin-loaded cationic liposomes in vitro and in H22 tumor-bearing mice.
    Chang M; Wu M; Li H
    Drug Deliv; 2018 Nov; 25(1):1984-1995. PubMed ID: 30499350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced siRNA delivery using cationic liposomes with new polyarginine-conjugated PEG-lipid.
    Kim HK; Davaa E; Myung CS; Park JS
    Int J Pharm; 2010 Jun; 392(1-2):141-7. PubMed ID: 20347025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The enhancement of gene silencing efficiency with chitosan-coated liposome formulations of siRNAs targeting HIF-1α and VEGF.
    Şalva E; Turan SÖ; Eren F; Akbuğa J
    Int J Pharm; 2015 Jan; 478(1):147-154. PubMed ID: 25445537
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro evaluation of optimized liposomes for delivery of small interfering RNA.
    Yang T; Bantegui T; Pike K; Bloom R; Phipps R; Bai S
    J Liposome Res; 2014 Dec; 24(4):270-9. PubMed ID: 24708056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Layer-by-layer polymer coated gold nanoparticles for topical delivery of imatinib mesylate to treat melanoma.
    Labala S; Mandapalli PK; Kurumaddali A; Venuganti VV
    Mol Pharm; 2015 Mar; 12(3):878-88. PubMed ID: 25587849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Toxicological exploration of peptide-based cationic liposomes in siRNA delivery.
    Zhu Y; Meng Y; Zhao Y; Zhu J; Xu H; Zhang E; Shi L; Du L; Liu G; Zhang C; Xu X; Kang X; Zhen Y; Zhang S
    Colloids Surf B Biointerfaces; 2019 Jul; 179():66-76. PubMed ID: 30947085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. STAT3 silencing in dendritic cells by siRNA polyplexes encapsulated in PLGA nanoparticles for the modulation of anticancer immune response.
    Alshamsan A; Haddadi A; Hamdy S; Samuel J; El-Kadi AO; Uludağ H; Lavasanifar A
    Mol Pharm; 2010 Oct; 7(5):1643-54. PubMed ID: 20804176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.